Poorva Bindal

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 5

Top Topics

Placebo Controlled

Tyrosine Kinase

Advanced Non Small Cell Lung Cancer

Top Venues

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

Leukemia & lymphoma

This page only lists publications with an associated author ORCID identifier.

Publications

Poorva Bindal, Mimi Najjar, Kelly Koehn, Amandeep Godara, Douglas W Sborov, Brian McClune, Kelley Julian, Charlotte Wagner, Ghulam Rehman Mohyuddin
Refractoriness to last line of therapy: how often is it mandated and reported? A systematic review of randomized myeloma trials. Leukemia & lymphoma (2023)
Poorva Bindal, Mimi Najjar, Kelly Koehn, Amandeep Godara, Douglas W Sborov, Brian McClune, Kelley Jullian, Charlotte Wagner, Ghulam Rehman Mohyuddin
Refractoriness to last line of therapy: how often is it mandated and reported? A systematic review of randomized myeloma trials. Leukemia & lymphoma (2023)
Nikhila Kethireddy, Steffi Thomas, Poorva Bindal, Prateek Shukla, Upendra Hegde
Multiple autoimmune side effects of immune checkpoint inhibitors in a patient with metastatic melanoma receiving pembrolizumab. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 27 (1) (2020)
Agnes McAuliffe, Poorva Bindal, Meredith Haley, James Vredenburgh
Treatment exceeds expectations in a patient with non-small cell lung adenocarcinoma with an EGFR exon 20 mutation. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 26 (1) (2019)
Vinay M Thomas, Poorva Bindal, Swetha Ann Alexander, Kymberly McDonald
Nivolumab-induced hepatitis: A rare side effect of an immune check point inhibitor. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 26 (2) (2019)